DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Stiff-Person syndrome — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleStiff-Person syndrome maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for stiff-person syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
gamma-aminobutyric acid type A receptor subunit alpha4 (GABRA4) — GABRA4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet px6drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7QN5 · 2.5 Å · ligand 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATE (PX6). Experimental structure, not a prediction.
What the evidence adds up to
Stiff person syndrome is a rare disorder of fluctuating rigidity in axial and proximal lower limb muscles, with superimposed painful spasms and continuous motor unit activity on electromyography. It remains underdiagnosed; left untreated it can progress to significant disability, poor quality of life, and excess comorbidity and mortality. A 2013 review notes it is an important autoimmune mediated disorder to consider in patients with unexplained pain and muscular rigidity.
A 1991 open-label trial of milacemide in three patients with stiff-person syndrome found no significant improvement at doses up to 2,400 mg/day. A 2025 systematic review of immune and symptomatic treatments included 36 studies — 21 case series, 10 cohort studies, and only five randomised controlled trials. Most studies assessed spasms and stiffness, but walking ability and pain were evaluated in less than half. Only 10 studies (28%) used a valid and reliable tool to assess functional improvement. The review highlights the paucity of data and heterogeneity in treatment responses. A 2019 summary of case reports on physical therapy intervention found no randomised clinical trials existed; it concluded that physical therapy training is substantiated as a necessary and beneficial intervention in rehabilitation, but the evidence base remains limited to case reports.
What is still missing are large, randomised controlled trials with standardised outcome measures. The 2025 review calls for standardised assessment methods in clinical practice to benefit understanding and approval of future therapy strategies. No drug has shown clear efficacy in a controlled setting. Patient stratification, funding for adequately powered trials, and consistent use of validated functional scales are all lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Practical Neurology · 2011 · 148 citations
Stiff person syndrome
AbstractStiff person syndrome (SPS) is a rare disorder, characterised by fluctuating rigidity and stiffness of the axial and proximal lower limb muscles, with superimposed painful spasms and continuous motor unit activity on electromyography. Although rare in general neurology practice, once observed it is unforgettable. The general neurologist may see only one or two cases during his or her career and as such it remains underdiagnosed. Left untreated, SPS symptoms can progress to cause significant disability. Patients have a poor quality of life and an excess rate of comorbidity and mortality. The severity of symptoms and lack of public awareness of the condition create anxiety and uncertainty for people with the disease. This review aims to raise awareness of SPS and to improve the likelihood of its earlier diagnosis and treatment.
BioMed Research International · 2019 · 13 citations · open access
Is Stiff Person Syndrome Benefited by Physical Therapy Intervention? Summary of Case Reports
AbstractIt is interesting to be aware that there is no Randomized Clinical Trials (RCT) research article except a few case-study reports which have been reported about the physical therapy (PT) intervention for stiff person syndrome (SPS). This study was designed to determine the benefits of PT in cases with SPS through analysis of case reports, thereby to raise awareness among physical therapist about the most beneficial PT interventions for SPS. We executed acomputer-based search with a diagnosis of SPS who underwent PT and articles published only in English. We selected case-study reports because of nonavailability of RCT articles to review the complaints, deformities, contractures, precipitating factors, interventions, outcomes, results, disability, and benefits of PT management among SPS. We concluded that PT training is substantiated to be a necessary and beneficial intervention in rehabilitation of patients with SPS.
A therapeutic trial of milacemide in myoclonus and the stiff‐person syndrome
AbstractWe investigated the therapeutic effects of milacemide in seven patients with myoclonus and three patients with the stiff-person syndrome in an open-label trial. Milacemide was initiated at 800 mg/day and was gradually increased to a maximum dosage of 2,400 mg/day. No significant improvement occurred in the 10 patients.
European Journal of Neurology · 2025 · 2 citations · open access
Systematic Review of Immune and Symptomatic Treatments for Stiff‐Person Syndrome
AbstractBACKGROUND AND PURPOSE: This systematic review evaluated the effectiveness and safety of immune and symptomatic treatments in patients with stiff-person syndrome (SPS). METHODS: A systematic search of PubMed, Embase, and the Cochrane Library was conducted up to September 30, 2024 in accordance with the PRISMA guidelines. All studies that involve SPS patients treated with symptomatic pharmacotherapy or immunotherapy and where the outcome is reported were included in the initial screening. Case reports were excluded. Two independent reviewers carried out study selection, bias assessment with the Murad et al. tool for case series, ROBINS-I for observational studies or RoB-2 for randomised trials, and data extraction into a predefined template. All available efficacy and safety data were recorded. A narrative synthesis was conducted to address the heterogeneity of the studies. RESULTS: Thirty-six studies were included. Most of the included studies consisted of small-scale studies, with 21 case series, 10 cohort studies and only five randomised controlled trials. Outcome assessments varied across the reviewed studies. Most studies assessed measures with subjective self-report and/or through clinical observations. Spasms and stiffness were assessed in around 60% of studies. Walking ability and pain were evaluated in less than half of studies. Only 10 (28%) studies assessed functional improvement using a valid and reliable tool. The present review highlights the paucity of data and the heterogeneity in SPS treatment responses and underscores the need for individualised therapeutic strategies. CONCLUSIONS: Standardised assessment methods in clinical practice are necessary to benefit understanding and approval of future therapy strategies.
Oxford University Press eBooks · 2013 · 0 citations
Stiff Person Syndrome
AbstractStiff person syndrome is an important autoimmune mediated disorder to consider in patients with unexplained pain and muscular rigidity. We review the proposed diagnostic criteria, common clinical features, and important serologic and electrophysiological tests to aid in diagnosis as well as medical and rehabilitative therapeutic options. In addition, we discuss the identification and management of possible paraneoplastic presentations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
